抗体片段市场机会、成长动力、产业趋势分析与预测 2024 - 2032

Antibody Fragments Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2024 - 2032

出版日期: 2024年10月01日 | 出版商:

Global Market Insights Inc. | 英文 200 Pages | 商品交期: 2-3个工作天内

价格

简介目录

2023 年，全球抗体片段市场价值为 73 亿美元，预计 2024 年至 2032 年复合年增长率为 5.6%。它们经过专门设计，保留其亲代抗体的结合特异性，同时提供独特的特性，使它们适合整个抗体效果较差的应用。市场成长的主要驱动力之一是对标靶治疗的需求不断增长。个人化医疗的兴起导致人们对提供高特异性的生物疗法越来越感兴趣。

抗体片段特别适合这些标靶治疗，特别是在肿瘤学和免疫学领域，因为它们能够针对特定抗原相互作用进行客製化。市场可依特异性分类，分为单株抗体和多株抗体。单株抗体类别包括针对特定治疗用途客製化的各种产品。相较之下，多克隆抗体片段具有不同的产品，旨在解决一系列健康问题。

到 2032 年，单株抗体领域预计将达到 75 亿美元，反映了该领域的持续创新。依类型分析市场，抗体片段又分为FAB、scFv、sdAb等类型。 2023 年，仅单链可变片段(scFv) 片段就占23 亿美元。治疗。它们较小的尺寸使它们能够接近具有挑战性的目标，例如位于组织深处或较大抗体可能无法有效到达的特定微环境中的肿瘤细胞。到2020 年将达到40 亿美元。

市场范围
开始年份	2023年
预测年份	2024-2032
起始值	73 亿美元
预测值	117 亿美元
复合年增长率	5.6%

该地区是全球癌症发病率最高的地区之一，这推动了对创新癌症疗法以及抗体片段的需求。此外，美国众多领先的生物技术和製药公司支持这些疗法的开发和商业化，进一步推动市场成长。随着对个人化和标靶治疗的需求持续增长，抗体片段市场预计将在未来几年取得重大进展和扩张。

产业生态系统分析
产业影响力
- 成长动力
  - 标靶治疗的需求不断增长
  - 癌症盛行率不断上升
  - 生物技术和基因工程的进展
  - 监管审批的增长
- 产业陷阱与挑战
  - 与单链可变片段稳定性相关的担忧
  - 开发成本高
成长潜力分析
技术景观
监管环境
未来市场趋势
波特的分析
管道分析
PESTEL分析

第 4 章：竞争格局

介绍
公司市占率分析
公司矩阵分析
主要市场参与者的竞争分析
竞争定位矩阵
战略仪表板

第 5 章：市场估计与预测：按具体情况，2021 - 2032 年

主要趋势
单株抗体
- Praxbind（伊达鲁珠单抗）
- 雷珠单抗（Lucentis）
- 聚乙二醇赛妥珠单抗（Cimzia）
- 碘 (I 311) 美妥昔单抗/利卡汀
- Beovu（Brolucizumab-dll）
- Cablivi（Caplacizumab-yhdp）
- 博纳吐单抗
多株抗体抗体
- 克罗法布
- 阿纳维普
- 阿纳斯公司
- 七价肉毒桿菌抗毒素
- 数码绑定
- 数码工厂

第 6 章：市场估计与预测：按类型，2021 - 2032

主要趋势
FAB
短链病毒
史达布
其他类型

第 7 章：市场估计与预测：按应用分类，2021 - 2032

主要趋势
癌症
免疫缺陷
其他应用

第 8 章：市场估计与预测：按地区，2021 - 2032

主要趋势
北美洲
- 我们
- 加拿大
欧洲
- 德国
- 英国
- 法国
- 西班牙
- 义大利
- 荷兰
- 欧洲其他地区
亚太地区
- 中国
- 日本
- 印度
- 澳洲
- 韩国
- 亚太地区其他地区
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 拉丁美洲其他地区
中东和非洲
- 南非
- 沙乌地阿拉伯
- 阿联酋
- 中东和非洲其他地区

第 9 章：公司简介

AbbVie Inc.
Amgen
AstraZeneca
BioNTech
Bristol-Myers Squibb Company
Eli Lilly and Company
Genentech, Inc.
Johnson & Johnson
Merck & Co.
MorphoSys
Novartis AG
Pfizer Inc.
Sanofi
Takeda Pharmaceutical Company Limited
UCB Pharma

简介目录

Product Code: 11679

The Global Antibody Fragments Market was valued at USD 7.3 billion in 2023 and is anticipated to grow at 5.6% CAGR from 2024 to 2032. Antibody fragments are smaller components derived from full-length monoclonal antibodies. They are specifically designed to retain the binding specificity of their parent antibodies while offering unique properties that make them suitable for applications where whole antibodies may be less effective. One of the primary drivers of market growth is the increasing demand for targeted therapies. The rise of personalized medicine has led to a growing interest in biologic therapies that provide high specificity.

Antibody fragments are particularly well-suited for these targeted therapies, especially in oncology and immunology, due to their ability to be tailored for specific antigen interactions. The market can be categorized based on specificity, dividing it into monoclonal antibodies and polyclonal antibodies. The monoclonal antibody category includes various products tailored for specific therapeutic uses. In contrast, the polyclonal antibody segment features different products designed to address a range of health concerns.

The monoclonal antibody segment is projected to reach USD 7.5 billion by 2032, reflecting the ongoing innovation in this area. When analyzing the market by type, antibody fragments are further classified into FAB, scFv, sdAb, and other types. The single-chain variable fragment (scFv) segment alone accounted for USD 2.3 billion in 2023. The growing prevalence of cancer significantly contributes to the success of the scFv segment, as these fragments are increasingly used in targeted cancer therapies. Their smaller size enables them to access challenging targets, such as tumor cells located deep within tissues or in specific microenvironments that larger antibodies may not reach effectively.In the United States, the antibody fragments market is assumed to expand significantly, reaching USD 4 billion by 2032.

Market Scope
Start Year	2023
Forecast Year	2024-2032
Start Value	$7.3 Billion
Forecast Value	$11.7 Billion
CAGR	5.6%

The region has one of the highest cancer rates globally, which drives the demand for innovative cancer therapies and, consequently, antibody fragments. Additionally, numerous leading biotechnology and pharmaceutical companies in the U.S. support the development and commercialization of these therapies, further propelling market growth. As the demand for personalized and targeted treatments continues to rise, the antibody fragments market is poised for significant advancements and expansion in the coming years.

Chapter 1 Methodology & Scope

1.1 Market scope & definitions
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates & calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360° synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Rising demand for targeted therapies
  - 3.2.1.2 Growing prevalence of cancer
  - 3.2.1.3 Advances in biotechnology and genetic engineering
  - 3.2.1.4 Growth in regulatory approvals
- 3.2.2 Industry pitfalls & challenges
  - 3.2.2.1 Concerns related to stability in single-chain variable fragments
  - 3.2.2.2 High development cost
3.3 Growth potential analysis
3.4 Technology landscape
3.5 Regulatory landscape
3.6 Future market trends
3.7 Porter's analysis
3.8 Pipeline analysis
3.9 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company market share analysis
4.3 Company matrix analysis
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Specificity, 2021 - 2032 ($ Mn)

5.1 Key trends
5.2 Monoclonal antibody
- 5.2.1 Praxbind (Idarucizumab)
- 5.2.2 Ranibizumab (Lucentis)
- 5.2.3 Certolizumab pegol (Cimzia)
- 5.2.4 Iodine (I 311) metuximab/ licartin
- 5.2.5 Beovu (Brolucizumab-dbll)
- 5.2.6 Cablivi (Caplacizumab-yhdp)
- 5.2.7 Blinatumomab
5.3 Polyclonal antibody
- 5.3.1 Crofab
- 5.3.2 Anavip
- 5.3.3 Anascorp
- 5.3.4 Botulism antitoxin heptavalent
- 5.3.5 Digibind
- 5.3.6 Digifab

Chapter 6 Market Estimates and Forecast, By Type, 2021 - 2032 ($ Mn)

6.1 Key trends
6.2 FAB
6.3 scfv
6.4 sdab
6.5 Other types

Chapter 7 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)

7.1 Key trends
7.2 Cancer
7.3 Immunodeficiency
7.4 Other applications

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

8.1 Key trends
8.2 North America
- 8.2.1 U.S.
- 8.2.2 Canada
8.3 Europe
- 8.3.1 Germany
- 8.3.2 UK
- 8.3.3 France
- 8.3.4 Spain
- 8.3.5 Italy
- 8.3.6 Netherlands
- 8.3.7 Rest of Europe
8.4 Asia Pacific
- 8.4.1 China
- 8.4.2 Japan
- 8.4.3 India
- 8.4.4 Australia
- 8.4.5 South Korea
- 8.4.6 Rest of Asia Pacific
8.5 Latin America
- 8.5.1 Brazil
- 8.5.2 Mexico
- 8.5.3 Argentina
- 8.5.4 Rest of Latin America
8.6 Middle East and Africa
- 8.6.1 South Africa
- 8.6.2 Saudi Arabia
- 8.6.3 UAE
- 8.6.4 Rest of Middle East and Africa